NMN Research & News: New Human Trials and 2026 Updates

NMN research in 2026 continues to show a consistent pattern: oral NMN can raise NAD+-related biomarkers in humans, while broader clinical benefits remain much less consistent.

New systematic reviews now include more randomized trials than were available only a few years ago. The safety picture is becoming clearer for short-term use, but evidence for long-term anti-aging, weight loss, glucose control, cognitive improvement, or lifespan extension remains limited or mixed.

This page tracks meaningful new NMN research and regulatory developments rather than repeating our evergreen guides.

Last updated: October 14, 2026

NMN Research 2026: The Main Takeaways

• Short-term randomized trials continue to show generally favorable tolerability.
• Blood NAD+ remains the most consistently changed human biomarker.
• Large, consistent improvements in weight, glucose control, lipids, or physical performance have not emerged across the evidence base.
• Results vary substantially by dose, formulation, population, and endpoint.
• Newer research increasingly focuses on who responds, rather than assuming everyone responds the same way.
• Long-term multi-year safety and clinical-outcome data remain limited.
• FDA's U.S. regulatory position changed materially in late 2025, while Europe continued a separate novel-food authorization process during 2026.

July 2026: New NMN Safety and Metabolism Meta-Analysis

A July 2026 systematic review and meta-analysis evaluated randomized controlled trials of oral NMN or closely related NMN preparations in adults.¹

The researchers included 15 trials overall, with 10 contributing to safety analyses.

Across the included studies:

• daily NMN amounts ranged from 250 mg to 2,000 mg;
• study duration ranged from 14 days to 24 weeks;
• overall adverse events were not significantly increased;
• serious adverse events were not significantly increased;
• withdrawals because of adverse events were not significantly increased;
• ALT and AST liver enzymes were not significantly elevated.

What About Metabolic Benefits?

The same analysis did not find significant overall effects on:

• body weight;
• BMI;
• fasting glucose;
• HbA1c;
• lipid profiles;
• systolic blood pressure.

A small reduction in diastolic blood pressure was reported, while HOMA-IR showed a nonsignificant downward trend.

The practical interpretation is straightforward:

Short-term tolerability looks more consistent than broad metabolic efficacy.

That distinction matters because NMN marketing often moves directly from “raises NAD+” to claims involving weight, metabolism, energy, or anti-aging. The current pooled human evidence does not support treating those as equivalent outcomes.

2026: Broader Review of NAD+ Boosters and Anti-Aging Claims

A 2026 PRISMA-guided systematic review examined human and rodent studies of NAD+-boosting strategies, including NMN, nicotinamide riboside, and NAD+ itself.²

The review included:

• 33 human intervention studies;
• 28 randomized human trials;
• 80 rodent studies.

The overall pattern was familiar:

• preclinical studies frequently reported metabolic, mitochondrial, inflammatory, or functional effects;
• human studies consistently demonstrated biochemical target engagement in some settings;
• human clinical outcomes were much more variable.

This is an important evidence boundary.

Strong rodent evidence does not mean oral NMN has been shown to reverse human aging or extend human lifespan.

June 2026: What Blood NAD+ Levels Actually Correlate With

A 2026 post hoc analysis examined blood NAD levels and laboratory measures in 80 healthy middle-aged adults from a previous randomized NMN trial.³

The original trial tested:

• 300 mg NMN daily;
• 600 mg daily;
• 900 mg daily;
• placebo;

for 60 days.

The newer analysis looked at whether NAD concentrations correlated with blood and metabolic variables before and after supplementation.

This type of analysis is useful because it moves the question beyond:

“Does NMN raise NAD+?”

toward:

“What does a higher blood NAD+ measurement actually mean clinically?”

That is likely to become a more important direction for NMN research, because simply demonstrating a higher NAD+ value does not prove a meaningful health benefit.

2026: Direct Comparison of NMN, NR and Nicotinamide

A randomized human study directly compared three NAD+-related precursors: NMN, nicotinamide riboside, and nicotinamide.⁴

Sixty-five healthy participants received one of the interventions for 14 days.

The researchers reported that:

• NMN increased circulating NAD+;
• NR also increased circulating NAD+;
• nicotinamide did not produce the same circulating NAD+ response under the tested conditions.

NMN and NR produced broadly comparable circulating NAD+ increases in this short study.

This is useful because it challenges overly simplistic claims that one precursor is automatically far more effective than another.

For the broader comparison, see our dedicated NMN vs NR guide.

2026: NMN, Exercise and Interoception

A 2026 randomized, double-blind, placebo-controlled study evaluated NMN together with pyrroloquinoline quinone, or PQQ, in the context of acute exhaustive exercise.⁵

The important limitation is that this was a combination intervention.

Results from an NMN + PQQ intervention should not automatically be attributed to NMN alone.

This is a recurring issue in supplement research:

• a combination product is tested;
• a change is observed;
• marketing later attributes the entire result to one ingredient.

That is not scientifically justified unless the study design isolates the contribution of each ingredient.

2025-2026: NMN in Acute Kidney Injury

A randomized controlled trial evaluated the pharmaceutical-grade microcrystalline β-NMN formulation MIB-626 in hospitalized adults with COVID-19 and acute kidney injury.⁶

Participants received:

• 1,000 mg MIB-626 twice daily; or
• placebo;

for 14 days.

NMN substantially increased blood NAD+ and several NAD-related metabolites.

However, the study did not find significant between-group differences in:

• serum creatinine;
• cystatin C;
• acute-kidney-injury markers;
• CRP;
• IL-6;
• TNF-alpha;
• clinical disease-severity indices.

This is another example of clear biochemical target engagement without a corresponding clear clinical-outcome improvement.

2026: A Larger Diabetic Kidney Disease Trial Is Underway

A 2026 published protocol describes a larger phase 2a randomized trial evaluating MIB-626 in adults with diabetic kidney disease.⁷

The trial is designed to include 156 participants and test:

• 1,000 mg MIB-626 twice daily;
• placebo;
• 24 weeks of treatment;
• 12 weeks of post-treatment follow-up.

This is important because many earlier NMN studies were:

• small;
• short;
• conducted in relatively healthy adults.

Larger disease-specific trials may provide more clinically useful answers.

A published trial protocol is not a positive clinical result. Outcomes should not be claimed until the trial is completed and reported.

2025 Meta-Analyses: Glucose and Lipid Effects Remain Weak

Several 2025 systematic reviews examined whether oral NMN meaningfully improves metabolic outcomes.

One meta-analysis included 12 studies and 513 participants.⁸

It found that NMN significantly increased blood NAD levels, but evidence for improvements in common glucose and lipid outcomes was limited.

Another review of randomized trials reported no significant overall benefit for:

• fasting glucose;
• fasting insulin;
• HbA1c;
• HOMA-IR;
• lipid profiles.⁹

This pattern is now fairly consistent across the literature:

raising NAD+ is easier to demonstrate than proving broad metabolic benefit.

2026 Blood Pressure Meta-Analysis

A 2026 systematic review and meta-analysis examined resting blood pressure in randomized NMN trials involving adults with elevated blood pressure.¹⁰

The analysis included 349 participants across 10 randomized trials.

This research adds to the emerging cardiovascular literature, but NMN should not be treated as a substitute for established blood-pressure therapy.

For practical safety questions, including blood pressure and medication use, see NMN side effects.

What Has Not Changed in the NMN Evidence?

Despite more human studies, several major claims remain unproven.

NMN has not been shown in humans to:

• extend lifespan;
• reverse biological aging;
• reliably produce weight loss;
• restore gray hair;
• regrow hair;
• reliably improve cognition;
• prevent cancer;
• prevent cardiovascular disease;
• act as a universal anti-aging treatment.

These remain much stronger claims than the current human evidence supports.

2026 FDA Update: NMN's U.S. Regulatory Status Changed

The most important recent U.S. regulatory development occurred in September 2025.

FDA stated that it no longer considers NMN excluded from the dietary-supplement definition under the drug-preclusion provision that had driven the 2022 controversy.

FDA's current New Dietary Ingredient database also lists notification 1444 for β-NMN/NMN:

• submitted November 17, 2025;
• FDA response dated January 28, 2026.

This does not mean NMN supplements are “FDA-approved.”

For the full regulatory history, see our NMN FDA-status guide.

2026 Europe Update: β-NMN Novel-Food Process Advances

The European Union regulates NMN differently from the United States.

NMN had previously been classified as a novel food in the EU.

During 2026, a chemically synthesized β-NMN application progressed through the novel-food process.

The proposed use was for adult food supplements, excluding pregnant and lactating women, at a proposed maximum intake of 500 mg per day.

In September 2026, the relevant EU Standing Committee issued a positive opinion on a draft implementing regulation authorizing β-NMN as a novel food.

This should not be summarized simply as:

• “NMN is banned in Europe”; or
• “every NMN product is now approved in Europe.”

EU novel-food authorization is tied to specific ingredient specifications and conditions of use.

What NMN Research Should We Watch Next?

Several areas are more important than simply producing additional small NAD+ biomarker studies.

1. Larger Disease-Specific Trials

Research in diabetic kidney disease and other clinical populations may clarify whether NAD+ increases translate into meaningful health outcomes.

2. Longer Follow-Up

Most NMN trials still last weeks or a few months.

Important unanswered questions include:

• multi-year safety;
• rare adverse events;
• long-term cancer-related outcomes;
• long-term cardiovascular effects.

3. Better Dose-Response Research

Higher doses do not automatically produce proportionally better outcomes.

Future studies need to determine whether there is an optimal exposure range rather than simply testing larger amounts.

4. Responder vs Nonresponder Research

Blood NAD+ responses vary substantially between individuals.

Understanding why may be more useful than assuming one dose fits everyone.

5. Head-to-Head Formulation Trials

Claims involving:

• liposomal NMN;
• sublingual NMN;
• powder;
• capsules;

need direct comparative human evidence rather than formulation theory.

How We Decide Which NMN Studies Matter

Not every new NMN paper deserves the same weight.

We prioritize evidence in roughly this order:

1. large randomized human trials;
2. smaller randomized human trials;
3. systematic reviews and meta-analyses;
4. human mechanistic or pharmacokinetic studies;
5. animal research;
6. cell-culture research.

A mouse longevity study should not be treated as equivalent to a human randomized clinical trial.

An NAD+ biomarker study should also not be presented as proof of a clinical anti-aging benefit.

NMN Research vs NMN Marketing

Marketing often compresses a chain of evidence into one claim:

1. NMN raises NAD+.
2. NAD+ participates in cellular metabolism.
3. aging is associated with changes in NAD+ biology.
4. therefore NMN reverses aging.

The first three statements can be scientifically relevant.

The fourth does not automatically follow.

Human research has to demonstrate the actual outcome.

Frequently Asked Questions

What is the latest NMN research?

The strongest 2026 update is a systematic review and meta-analysis showing generally favorable short-term tolerability across randomized trials but no broad significant improvement in weight, glucose control, HbA1c, lipids, or systolic blood pressure.

Does new research show NMN works?

NMN clearly has biological activity and can raise circulating NAD+-related biomarkers. Whether that translates into clinically meaningful benefits depends on the specific outcome, and many outcomes remain mixed or unproven.

Is NMN safe according to the latest studies?

Short-term randomized-trial data are generally reassuring, including no clear increase in overall adverse events or liver-enzyme abnormalities in recent pooled analyses. Multi-year safety remains uncertain.

Does NMN help with weight loss?

Current pooled randomized evidence does not show a significant overall effect on body weight or BMI.

Does NMN improve blood sugar?

Some individual studies report metabolic effects in specific populations, but recent meta-analyses do not show broad consistent improvements in fasting glucose, HbA1c, or insulin-related outcomes across adults.

Does NMN increase NAD+?

Yes. Raising circulating NAD+-related biomarkers is one of the most consistent findings across human NMN trials.

Does raising NAD+ mean NMN slows aging?

No. A biomarker change does not demonstrate slower human aging, lower mortality, or extended lifespan.

Has NMN been proven to extend lifespan in humans?

No human trial has shown that NMN supplementation extends lifespan.

Are there new 2026 NMN clinical trials?

Yes. New publications include systematic reviews, post hoc human analyses, combination-intervention trials, and protocols for larger disease-specific randomized studies.

Is NMN FDA-approved now?

No. FDA changed its regulatory interpretation regarding NMN's dietary-supplement status, but dietary supplements are not FDA-approved for safety and effectiveness before marketing.

Is NMN legal in the U.S.?

FDA no longer considers NMN excluded from the dietary-supplement definition under the drug-preclusion provision that drove the 2022 controversy. See our dedicated FDA-status article for details.

Is NMN approved in Europe?

A specific β-NMN novel-food application advanced substantially in 2026, including a positive committee opinion on a draft authorization. EU status is application- and specification-specific.

The Bottom Line

NMN research is maturing, but the central scientific picture has not flipped.

The strongest current conclusions are:

• oral NMN can reliably increase NAD+-related biomarkers in humans;
• short-term tolerability is generally favorable in published randomized trials;
• broad metabolic benefits remain inconsistent;
• weight-loss effects are not established across trials;
• glucose and lipid improvements are not consistently demonstrated;
• some functional or vascular signals are interesting but require confirmation;
• larger and longer disease-specific trials are now more important than additional small biomarker studies;
• human lifespan extension and reversal of aging remain unproven.

This page will continue to track new research as it appears.

For evergreen topics, see what NMN is, NMN benefits, NMN dosage, NMN side effects, and NMN FDA status.

References

1. Yang W, Huang J, Tang Z, et al. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(14):2251. PMID: 42514320.
2. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. PMID: 41655607.
3. Kuerec AH, Wang W, Fokke KDM, et al. Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial. GeroScience. 2026;48(3):3305–3313. PMID: 41162813.
4. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. 2026. PMID: 41540253.
5. Zhao C, Wu B, Sui H, et al. The effects of pyrroloquinoline quinone and nicotinamide mononucleotide supplementation on interoception following acute exhaustive exercise: a randomised, double-blind, placebo-controlled study. Scientific Reports. 2026;16:5408. PMID: 41651893.
6. Pencina KM, Leaf DE, Valderrabano RJ, et al. Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial. FASEB BioAdvances. 2025;7(8):e70011. PMID: 40746868.
7. Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol. 2026. PMID: 42603990.
8. Zhang J, Poon ETC, Wong SHS. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Critical Reviews in Food Science and Nutrition. 2025. PMID: 39116016.
9. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. 2025. PMID: 39531138.
10. Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2026. PMID: 41901064.
11. U.S. Food and Drug Administration. Submitted 75-Day Premarket Notifications for New Dietary Ingredients. NDI 1444: β-NMN/NMN; response dated January 28, 2026.
12. European Commission. Draft Commission Implementing Regulation authorising the placing on the market of β-NMN as a novel food. Positive committee opinion, September 24, 2026.